

(Print or Type Responses)

1. Name and Address of Reporting

Reporting Owner Name / Address

C/O CELLECTAR BIOSCIENCES, INC.

Weichert Jamey P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Weekington, D.C. 20540

Washington, D.C. 20549

OMB APPROVAL OMB 3235Number: 0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Person * Weichert Jamey P	(Mo	ement nth/Day/Year)	Cellectar Biosciences, Inc. [CLRB]				
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE (Street)		08/14/2014		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director _X_Officer (give Other (specif				
				title below) below) Chief Scientific Officer			6. Individual or Joint/Group Filing(Check Applicable Line)	
MADISON, WI 53716								led by One Reporting Person ed by More than One Reporting
(City) (State) ((Zip)	Tal	ole I - Noi	1-Derivati	ive Securition	es Ben	eficially	Owned
1.Title of Security (Instr. 4)		Ben	amount of S eficially Ov tr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Owne	rship	rect Beneficial
Common Stock, par value \$	0.00001 per	share 235	5,336		D			
not requir number.	e Securities B 2. Date Exe Expiration I (Month/Day/Ye	ration Date Secur \(\text{Day/Year}\) Deriver (Instr.		g., puts, calls, warrants, op and Amount of ies Underlying tive Security 4. Conversion Exer Price of		tions, consistence of the constant of the cons	onvertible wnership	securities) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount of Number of Shares	Security	Derivative S Security C (
Employee Stock Option (right to buy)	<u>(1)</u>	12/13/2023	Stock	12,500	\$ 7.4		D	
Employee Stock Option (right to buy)	<u>(1)</u>	12/14/2022	Common Stock	6,250	\$ 15		D	
Employee Stock Option (right to buy)	<u>(1)</u>	12/16/2021	Common Stock	a 3,400	\$ 9		D	
Employee Stock Option (right to buy)	(1)	05/18/2021	Common	ⁿ 6,800	\$ 28		D	
Reporting Owner	rs							

Relationships

Director 10% Owner Officer

Other

3301 AGRICULTURE DRIVE MADISON, WI 53716	X	Chief Scientific Officer	
Signatures			_

/s/ Paul Bork,attorney-in-fact for Jamey P. Weichert	08/14/2014
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option vests in equal quarterly increments over a period of three years from the date of grant. Option expires on the tenth anniversary of the date of grant.

Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

C	with respect to securities of Cellectar Bi onfirming statement.	osciences, Inc. who is not named herein,	, and this Statement replaces and supersedes any
Dated:	August 8, 2014	Signed:	/s/ Jamey P. Weichert
		Print Name:	Jamey P. Weichert

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing